CAR-T Cell Therapy in Large B Cell Lymphoma

Large B-cell lymphomas (LBCLs) are among the most frequent (about 30%) non-Hodgkin’s lymphoma. Despite the aggressive behavior of these lymphomas, more than 60% of patients can be cured with first-line chemoimmunotherapy using the R-CHOP regimen. Patients with refractory or relapsing disease show a...

Descripción completa

Detalles Bibliográficos
Autores principales: Testa, Ugo, Leone, Giuseppe, Pelosi, Elvira, Castelli, Germana, Hohaus, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631715/
https://www.ncbi.nlm.nih.gov/pubmed/38028399
http://dx.doi.org/10.4084/MJHID.2023.066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631715/
https://www.ncbi.nlm.nih.gov/pubmed/38028399
http://dx.doi.org/10.4084/MJHID.2023.066

Ejemplares similares